相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas
Justyna M. Przystal et al.
NEURO-ONCOLOGY (2022)
ONC201 and ONC206: Metabolically ClipPing the wings of diffuse midline glioma
Benjamin Purow
NEURO-ONCOLOGY (2022)
Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data
Gauthier Bouche et al.
LANCET ONCOLOGY (2021)
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Jo Ishizawa et al.
CANCER CELL (2019)
Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials
Nicholas A. Vitanza et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2019)
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Andrew S. Chi et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Grant L. Lin et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries
Lindsey M. Hoffman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
Isabel Arrillaga-Romany et al.
ONCOTARGET (2017)
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N. Stein et al.
CLINICAL CANCER RESEARCH (2017)
The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
Jessica Wagner et al.
ONCOTARGET (2014)
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group
Kenneth J. Cohen et al.
NEURO-ONCOLOGY (2011)
分享论文
